FIT Biotech Oy
Company Release, October 1, 2015 at 9:00 EET
Notice convening an extraordinary general meeting of FIT Biotech Oy
The shareholders of FIT Biotech Oy are invited to an extraordinary general meeting, which is to be held on Thursday, 22 October 2015 starting at 12:00 noon at the offices of Castrén & Snellman Attorneys Ltd at Eteläesplanadi 14 (6th floor), 00130 Helsinki, Finland. The reception of persons who have registered for the meeting will begin at 11:30.
A. Matters on the Agenda of the General Meeting
At the general meeting, the following matters will be considered:
- Opening of the meeting
- Calling the meeting to order
- Election of persons to scrutinise the minutes and to count the votes
- Recording the legality of the meeting
- Recording the attendance at the meeting and adoption of the list of votes
- Resolution on the number of the members of the board of directors
The board of directors proposes to the general meeting that the number of members of the board of directors be confirmed as six (6).
- Election of members of the board of directors
The board of directors proposes to the general meeting that Tomi Numminen and Rabbe Klemets be elected as new members of the board of directors and that current members of the board Rabbe Slätis, Erkki Pekkarinen, Dirk Teuwen and Juha Vapaavuori be re-elected as members of the board of directors for a term of office that expires at the end of the first annual general meeting following the election. All candidates have consented to being re-elected.
- Closing of the meeting
B. Documents of the General Meeting
The aforementioned proposals for resolutions on the matters on the agenda of the general meeting as well as this notice are available on FIT Biotech Oy's website at the address www.fitbiotech.com and at the head office at the latest as of 1 October 2015. The documents of the general meeting are also available at the general meeting and copies will be delivered to shareholders upon request. The minutes of the general meeting will be available on the company's website and at the head office at the latest as of 5 November 2015.
C. Instructions for the Participants in the General Meeting
1. Shareholders Registered in the Shareholders' Register
Each shareholder who is registered on 12 October 2015 in the shareholders' register of the company held by Euroclear Finland Ltd has the right to participate in the general meeting. A shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the shareholders' register of the company.
A shareholder who is registered in the shareholders' register of the company and who wants to participate in the general meeting has to register for the meeting no later than on 19 October 2015 at 10:00 a.m. by e-mail to the address liisa.laitinen@fitbiotech.com or by post to the address FIT Biotech Oy/Liisa Laitinen, Biokatu 8, 33520 Tampere, Finland, by which time the registration must be received by the company. The shareholder's name and personal identification number or business ID, address, telephone number as well as the name of a possible assistant or proxy representative and the personal identification number of a proxy representative must be provided in connection with the registration. The personal data provided by the shareholders to the company is only used in connection with the general meeting and with the necessary processing of related registrations.
The shareholder, his/her authorised representative or proxy representative must, if necessary, be able to prove his/her identity and/or right of representation at the general meeting.
2. Holders of Nominee Registered Shares
A holder of nominee registered shares has the right to participate in the general meeting based on the shares that would entitle him/her to be registered in the shareholders' register held by Euroclear Finland Ltd on 12 October 2015. In addition, the right to participate requires that holders of nominee registered shares be temporarily entered into the shareholders' register held by Euroclear Finland Ltd based on these shares by 19 October 2015, 10:00 a.m., at the latest. As regards nominee registered shares this constitutes due registration for the general meeting.
A holder of nominee registered shares is advised to request without delay necessary instructions regarding the registration in the temporary shareholder's register of the company, the issuing of proxy documents and registration for the general meeting from his/her custodian bank. The account operator of the custodian bank has to temporarily register a holder of nominee registered shares who wants to participate in the general meeting into the shareholders' register of the company at the latest by the time stated above.
3. Proxy Representatives and Powers of Attorney
A shareholder may participate in the general meeting and exercise his/her rights at the meeting by way of proxy representation. A proxy representative must produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the extraordinary general meeting. When a shareholder participates in the general meeting by means of several proxy representatives representing the shareholder with shares in different securities accounts, the shares by which each proxy representative represents the shareholder must be identified in connection with registration for the general meeting. Any proxy documents and powers of attorney are requested to be delivered by post to the address FIT Biotech Oy/Liisa Laitinen, Biokatu 8, 33520 Tampere, Finland or by e-mail to the address liisa.laitinen@fitbiotech.com at the latest on 19 October 2015.
Tampere 1 October 2015
FIT Biotech Oy
Board of directors
Additional information:
CEO Kalevi Reijonen, FIT Biotech Oy
Email: kalevi.reijonen@fitbiotech.com
Phone: +358 40 843 5695
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.
Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.
FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com